multiple sclerosis

News

First Tysabri biosimilar cleared by FDA for MS

Sandoz and Polpharma Biologics have become the first companies to get FDA approval for a biosimilar of Biogen's blockbuster multiple sclerosis therapy Tysabri, after overc

News

Roche preps filings for new Ocrevus injection

A subcutaneous (SC) injection version of Roche’s big-selling multiple sclerosis therapy Ocrevus has matched the current intravenous form in a clinical trial and, according

News

Sanofi scores in MS with CD40 antibody frexalimab

Sanofi has posted encouraging results with one of its mid-stage candidates for multiple sclerosis, anti-CD40L

News

Roche’s BTK drug fenebrutinib hits the mark in MS

Roche has made its case for BTK inhibitor fenebrutinib as a potential new oral therapy for multiple sclerosis, with a phase 2 readout that it says shows significant improv

News

FDA slaps clinical hold on Merck’s MS drug evobrutinib

Germany’s Merck KGaA said this morning that the FDA has placed a partial clinical hold on its multiple sclerosis drug candidate evobrutinib, vying to become a new oral the

R&D

Novartis’ Kesimpta, ECTRIMS 2022, and relapsing multiple scl...

Having presented new data at last year’s European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting – where the safety and efficacy of Novartis’ Kesimpta (

First Tysabri biosimilar cleared by FDA for MS

Roche preps filings for new Ocrevus injection

Sanofi scores in MS with CD40 antibody frexalimab

Roche’s BTK drug fenebrutinib hits the mark in MS

FDA slaps clinical hold on Merck’s MS drug evobrutinib

Novartis’ Kesimpta, ECTRIMS 2022, and relapsing multiple scl...

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

multiple sclerosis

Editor's Picks